Nuvectis Pharma, Inc. (NASDAQ: NVCT)

Sector: Healthcare Industry: Biotechnology CIK: 0001875558
Market Cap 195.10 Mn
P/B 10.60
P/E -6.76
P/S 0.00
ROIC (Qtr) -130.00
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, operates in the development of innovative precision medicines for the treatment of severe conditions of unmet medical need in oncology. Its main business activities revolve around the development of drug candidates in the precision medicine space, focusing on cancer-promoting factors and clinical landscape and regulatory requirements. Nuvectis Pharma generates revenue through the development and commercialization of its product candidates, including NXP800 and NXP900. NXP800 is...

Read more

Investment thesis

Bull case

  • Tangible assets of 31.71M provide robust 4.52x coverage of other current liabilities 7.02M, indicating strong asset backing.
  • Cash reserves of 31.63M provide robust 2.38x coverage of current liabilities 13.30M, indicating strong short-term solvency.
  • Strong cash position of 31.63M provides 4.50x coverage of other current liabilities 7.02M, indicating excellent liquidity.
  • Cash position of 31.63M represents healthy 1.72x of working capital 18.41M, demonstrating strong operational liquidity.
  • Robust R&D investment of 18.15M at 1.93x of SG&A 9.42M demonstrates strong commitment to innovation and future growth.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 18.15M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • High financing cash flow of 29.11M relative to working capital of 18.41M, which is 1.58x suggests concerning dependence on external funding for operational needs.
  • Operating cash flow of (16.01M) is outpaced by equity issuance of 29.11M (-0.55 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 31.71M provide limited backing for working capital of 18.41M, which is 1.72x, suggesting increased operational risk in market downturns.
  • Operating cash flow of (16.01M) provides only -0.88x coverage of R&D expenses of 18.15M, suggesting vulnerability in maintaining innovation investments.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 5.04 11.06
EV to Cash from Ops. EV/CFO -9.97 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -6.04 -13.49
EV to EBITDA EV/EBITDA -5.79 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -9.97 25.66
EV to Market Cap EV to Market Cap 0.82 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 10.60 20.59
Price to Earnings [P/E] P/E -6.76 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) -11.89 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Interest Coverage 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 70.69 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -39.17 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -38.93 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -39.17 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -39.17 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -18.92 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -30.72 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 2.38 3.92
Current Ratio Curr Ratio (Qtr) 2.39 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Interest Cover Ratio 0.00 956.66
Times Interest Earned Times Interest Earned 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % 0.00 -17,888.70
EBIT Margin % EBIT Margin % 0.00 -18,246.34
EBT Margin % EBT Margin % 0.00 -19,108.08
Gross Margin % Gross Margin % 0.00 -10.30
Net Profit Margin % Net Profit Margin % 0.00 -19,056.96